Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Zweiker, D; Manninger, M; Sieghartsleitner, R; Ebner, J; Pratl, B; Bisping, E; Lercher, P; von Lewinski, D; Riedlbauer, R; Rohrer, U; Spronk, HMH; Zirlik, A; Schotten, U; Scherr, D.
No antiarrhythmic effect of direct oral anticoagulants versus vitamin K antagonists in paroxysmal atrial fibrillation patients undergoing catheter ablation.
Int J Cardiol. 2021; 331(3):106-108 Doi: 10.1016/j.ijcard.2021.01.003
Web of Science PubMed FullText FullText_MUG

Führende Autor*innen der Med Uni Graz: Zweiker David
Co-Autor*innen der Med Uni Graz: Bisping Egbert Hubertus; Ebner Jakob; Lercher Peter; Manninger-Wünscher Martin; Riedlbauer Rita Andrea; Rohrer Ursula; Scherr Daniel; Sieghartsleitner Raphael; von Lewinski Dirk; Zirlik Andreas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Direct oral anticoagulants (DOACs) are superior to vitamin K antagonists (VKAs) for the prevention of stroke in atrial fibrillation (AF) patients with elevated stroke risk. Possible antiarrhythmic effects of DOACs have been discussed. We analyzed impact of DOAC treatment on recurrence-free survival after AF catheter ablation. Two-hundred and thirty-nine consecutive patients (median age 57 [IQR 48-64] years, 26.4% female) undergoing ablation for paroxysmal AF were included into this study. 68.6% of them received DOACs (DOAC group), 31.4% VKA (VKA group). The primary outcome was arrhythmia-free one-year survival. DOAC patients had lower BMI, shorter history of AF, less arterial hypertension, less vascular disease, less use of antiarrhythmics and consequently lower CHA₂DS₂-VASc and HAS-BLED Scores. There was no difference in arrhythmia-free survival between DOAC and VKA groups (DOAC: 86.6%, VKA: 76.7%, p = 0.286). Despite baseline characteristics favouring a better outcome of DOAC patients, arrhythmia-free survival was similar in both groups. Consequently, DOAC treatment did not have clinically relevant antiarrhythmic properties in these patients. Copyright © 2021 Elsevier B.V. All rights reserved.
Find related publications in this database (Keywords): Anticoagulation; Catheter ablation; Atrial fibrillation; Vitamin K antagonist; Direct oral anticoagulants